Skip to main content
Delfa

← Trials/Trial dossier/NCT01937013

IEMO

CompletedPhase 2

Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia

Asset

Oxytocin

Listed sites

1

Recruiting sites

-

Enrollment

52

actual

Study population

Frontotemporal dementia

Key I/E criteria

•MMSE ≥27•MRI contraindications excluded•History of intracranial hemorrhage excluded

Primary endpoint

•Functional magnetic resonance imaging (fMRI) BOLD signal

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Secondary ID103555Western HSREB
Secondary ID166786Health Canada
Secondary IDFTDOXY13EFInternal
NCT IDNCT01937013
Org study IDR-13-270

Timeline

Milestones

Study first posted2013-09-09estimated
Study start2013-09-12actual
Primary completion2017-12-21actual
Study completion2017-12-21actual
Last update posted2018-08-08actual

Assets

Drug assets

Oxytocin

Study populations

Who this study enrolls

Frontotemporal dementia

Eligibility

Who can enroll

Minimum age30 Years
Maximum age85 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

Patients:

•Ages 30-85
•meet consensus criteria for probable behavioural variant FTD (bvFTD)

Controls:

•Age and sex matched with patients
•Mini-Mental State Exam (MMSE) scores >27

Exclusion criteria

Patients:

•history of stroke
•intracranial haemorrhage or other medical or neurological disorder apart from FTD that could affect cognition
•diagnosis of bipolar disorder or schizophrenia not better accounted for by the diagnosis of FTD
•cognitive impairment that precludes comprehension of task instructions
•contraindication to MRI scanning
•severe language or memory deficits that preclude participation in the study visits and measures
•females who are pregnant or breastfeeding (a pregnancy test will be done on females who have not completed menopause).
•uncontrolled hypertension
•bradycardia (rate <48 bpm) or tachycardia (rate > 100 bpm)
•current use of prostaglandins

Controls:

•history of stroke
•intracranial haemorrhage or other medical or neurological disorder
•diagnosis of bipolar disorder or schizophrenia
•cognitive impairment that precludes comprehension of task instructions
•contraindication to MRI scanning
•severe language or memory deficits that preclude participation in the study visits and measures
•females who are pregnant or breastfeeding (a pregnancy test will be done on females who have not completed menopause).
•uncontrolled hypertension
•bradycardia (rate <48 bpm) or tachycardia (rate > 100 bpm)
•current use of prostaglandins

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Neuroimaging
1
Other (unclassified)
1

Neuroimaging

1 endpoint
Primary/protocol endpoint

Functional magnetic resonance imaging (fMRI) BOLD signal

Time frame:2 weeks

descriptive

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Cognitive and Emotional Task performance

Time frame:2 weeks

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.